For some agents, the benefit appears to be enriched in PD-L1+ patients; however, because only 20–30% of RCC tumors express PD-L1 and tumor responses can be seen in patients with PD-L1- tumors, the number of responders with PD-L1- tumors can exceed those with PD-L1+ tumors. The gene discussed is CD274; the disease is renal cell carcinoma.